|
|
|
|
|
|
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative Breast Cancer (TNBC) VACCINE VS Standard-Of-Care For The Neoadjuvant Treatment Of Subjects With TNBC
This is a randomized open-label phase 2 study to evaluate the efficacy and safety (as assessed by pCR) of the NANT Neoadjuvant TNBC Vaccine regimen (experimental arm) compared to the SoC dose-dense regimen of doxorubicin/cyclophosphamide followed by paclitaxel (control arm).
100 项与 CEA x CD 66抗原 相关的临床结果
100 项与 CEA x CD 66抗原 相关的转化医学
0 项与 CEA x CD 66抗原 相关的专利(医药)